Analysts See $-0.13 EPS for Achillion Pharmaceuticals, Inc. (ACHN)

July 14, 2018 - By Robert Sims

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment decreased to 0.95 in 2018 Q1. Its down 1.13, from 2.08 in 2017Q4. It turned negative, as 26 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 17 funds opened positions while 35 raised stakes. 107.48 million shares or 2.61% less from 110.36 million shares in 2017Q4 were reported.
163,700 are held by California Pub Employees Retirement System. Geode Mgmt Lc owns 1.29 million shares. State Board Of Administration Of Florida Retirement holds 0% or 75,246 shares. Alliancebernstein Lp holds 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 159,100 shares. 62,850 are owned by Raymond James And Assoc. Financial Architects has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Meeder Asset Mngmt holds 1,263 shares. Parametric Associates Limited Liability Com invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Numerixs Tech reported 7,796 shares or 0.01% of all its holdings. Teacher Retirement Of Texas accumulated 0% or 24,234 shares. Goldman Sachs Gru holds 0.01% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 5.69M shares. Pub Employees Retirement Association Of Colorado owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 27,160 shares. Metropolitan Life Company New York has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Fmr Limited Co stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Acadian Asset Mgmt Ltd owns 82,478 shares or 0% of their US portfolio.

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.13 EPS on August, 14.They anticipate $0.03 EPS change or 18.75 % from last quarter’s $-0.16 EPS. After having $-0.15 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see -13.33 % EPS growth. The stock increased 7.17% or $0.21 during the last trading session, reaching $3.14. About 3.48M shares traded or 210.42% up from the average. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 13.49% since July 14, 2017 and is downtrending. It has underperformed by 26.06% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 3 analysts covering Achillion Pharmaceuticals (NASDAQ:ACHN), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Achillion Pharmaceuticals had 4 analyst reports since February 8, 2018 according to SRatingsIntel. Barclays Capital upgraded it to “Hold” rating and $500 target in Monday, May 21 report. FBR Capital initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Wednesday, February 7 with “Hold” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Hold” rating by FBR Capital on Friday, February 23.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $434.39 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

More notable recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Fool.com which released: “Better Buy: Inovio Pharmaceuticals, Inc. vs. Achillion Pharmaceuticals, Inc.” on June 22, 2018, also Streetinsider.com with their article: “Achillion Pharma (ACHN) Commences Phase I First-in-Human Study of ACH-5548” published on July 10, 2018, Nasdaq.com published: “Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement …” on July 10, 2018. More interesting news about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were released by: Nasdaq.com and their article: “Achillion to Present at the 2018 JMP Securities Life Sciences Conference” published on June 14, 2018 as well as Seekingalpha.com‘s news article titled: “Achillion Pharmaceuticals – Biotech Gold For The Price Of Dirt” with publication date: July 09, 2018.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: